Glycosylation of Immune Receptors in Cancer

Evading host immune surveillance is one of the hallmarks of cancer. Immune checkpoint therapy, which aims to eliminate cancer progression by reprogramming the antitumor immune response, currently occupies a solid position in the rapidly expanding arsenal of cancer therapy. As most immune checkpoints are membrane glycoproteins, mounting attention is drawn to asking how protein glycosylation affects immune function. The answers to this fundamental question will stimulate the rational development of future cancer diagnostics and therapeutic strategies.

Automated summary

Evasion of host immune surveillance is a hallmark of cancer, and immune checkpoint therapy aims to eliminate cancer progression by reprogramming the antitumor immune response. Understanding the impact of protein glycosylation on immune function will drive the rational development of future cancer diagnostics and therapeutic strategies.